Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics
Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics
Disruptive Technology Advances in SynBio Foster a Thriving Stakeholder Ecosystem and Accelerate Biopharma Developments
29-Jun-2023
Global
Technology Research
Description
The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization.
Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases.
Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities.
Information provided in this report includes the following:
• Growth drivers and restraints (2023–2027)
• Developments in SynBio technologies supporting drug discovery
• Critical challenges in developing SynBio therapeutics and the steps taken to address them
• Global market participants with potential
Table of Contents
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on SynBio in the Drug Discovery and Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
SynBio Emerges as a Promising Tool in R&D
Growth Drivers
Growth Restraints
Scope of Analysis
Segmentation
Technology Maturity
Emerging Companies, 2020–2022
Trends
Key Findings
Gene Circuits and CRISPR Systems Identify Novel Targets
SynBio Platforms Accelerate the Design and Development of Advanced Therapeutics
Role of SynBio Approaches in the Drug Discovery Pipeline
Target Identification and Drug Molecule Screening Using SynBio-driven Approaches
Advanced CRISPR Systems for Improved Drug Target Screening
Complex Gene Circuits Act as a Tool for Real-time Monitoring of Drug Discovery
Advanced Synthetic Circuit Platforms Enable High-throughput Drug Screening and Selection
Organ-on-a-chip and Organoid Systems Speed SynBio-driven Drug Discovery
Improving the Design of SynBio Tools to Address Challenges in Drug Discovery
The Growing Network of SynBio-driven Drug Discovery Companies
Developing Next-generation Therapeutics Using SynBio Tools
Controlled Therapeutic Responses Achieved Using SynBio Tools
SynBio Platform Adoption Can Transform Global Disease Treatment
Developing Advanced Therapeutics and Vaccines with SynBio Tools
Industry Players Developing Advanced Therapeutics and Vaccines Using SynBio Tools
SynBio Tools Enable the Development of Smart Cell Therapies
Logic Gates Improve the Engineered Cellular Activity with a Precise Switch On/Off Mechanism
R&D Efforts Focus on Developing Suitable SynBio Circuit/System
R&D Players Developing Programmable Medicine Using Gene Circuits
Multifunctional Chassis Organisms Used as Therapeutics Improve Scalability and Delivery
Developing Synthetically Engineered Microbiome Therapies
Engineered Microorganisms n Functioning as Live Therapeutics
Biosensors Identify Drug Targets and Release Therapeutics with Sensitivity
Cell-free Biomanufacturing of Therapeutics Using Gene Circuits
Growing Applications and Demand for Cell-free Biomanufacturing Systems
Encouraging Global Funding Activities to Boost the Growth f SynBio Platforms
Growing Mergers & Acquisitions o Improve SynBio Platform Capabilities
Growing Partnerships Between SynBio Therapy Developers and Pharmaceutical Companies
Global SynBioPlatforms or Accelerated Drug Discovery and Therapeutics
Gap Analysis for SynBio-based Therapies
Gap Analysis for SynBio-based Therapies (continued)
Living ell Therapeutics to Release Therapies Based on Gene Circuits
Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits
Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits (continued)
Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms
Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms (continued)
Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics
Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics (continued)
Advanced SynBio DBTL Cycle Speeds Drug Discovery
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Popular Topics
Deliverable Type | Technology Research |
---|---|
Author | Neeraja Vettekudath |
Industries | Healthcare |
No Index | No |
Is Prebook | No |
Keyword 1 | synthetic biology |
Keyword 2 | drug development research |
Keyword 3 | new drug discovery |
Podcast | No |
WIP Number | DAA1-01-00-00-00 |